

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/587,052
Filing Date	04-09-2007
First Named Inventor	Bunn Jr.
Art Unit	1642
Examiner Name	AEDER, SEAN E
Attorney Docket Number	2848-65-PUS

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
-----------------------	--------------------------	---	--------------------------------	--	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² , Number ⁴ , Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	1	WO 2004/063709	07/29/04	SQUIBB BRISTOL MYERS CO		
	2	WO 2005/067667	07/28/05	SQUIBB BRISTOL MYERS CO		
	3	WO 2005/094332	10/13/05	SQUIBB BRISTOL MYERS CO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. ¹	
	4	BASELGA et al., "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Five Selected Solid Tumor Types" Journal of Clinical Oncology, 2002, Vol. 20, No. 21, pages 4292-4302
	5	CHINNAIYAN ET AL. "Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition", Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings, Vol. 22, No. 14S, 3029
	6	DEEB ET AL., "Altered E-Cadherin and Epidermal Growth Factor Receptor Expressions are Associated with Patient Survival in Lung Cancer: A Study Utilizing High-Density Tissue Microarray and Immunohistochemistry", Modern Pathology, 2004, Vol. 17, pages 430-439

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/587,052
Filing Date	04-09-2007
First Named Inventor	Bunn Jr.
Art Unit	1642
Examiner Name	AEDER, SEAN E
Attorney Docket Number	2848-65-PUS

Sheet 2 of 2

7	WITTA ET AL., "Genes and Proteins Involved in Predicting Sensitivity/Resistance to Gefitinib in Lung Cancer", presented at the October 29, 2004 Meeting for the European Society for Medical Oncology (EMSO), 1 page
8	International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US2005/002325, issued July 24, 2006 (Attorney's Ref. No. 2848-65-PCT)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.